Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0960
-0.0020 (-2.04%)
Feb 19, 2026, 4:10 PM AEST
Neurizon Therapeutics Revenue
In the fiscal year ending June 30, 2025, Neurizon Therapeutics had annual revenue of 1.54M AUD with 82.70% growth. Neurizon Therapeutics had revenue of 6.40K in the half year ending June 30, 2025.
Revenue
1.54M
Revenue Growth
+82.70%
P/S Ratio
43.88
Revenue / Employee
384.46K
Employees
4
Market Cap
67.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.54M | 696.12K | 82.70% |
| Jun 30, 2024 | 841.71K | -31.94K | -3.66% |
| Jun 30, 2023 | 873.65K | -3.64M | -80.63% |
| Jun 30, 2022 | 4.51M | 853.24K | 23.33% |
| Jun 30, 2021 | 3.66M | -463.19K | -11.24% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Alterity Therapeutics | 5.44M |
| Amplia Therapeutics | 5.01M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |